PortalPublikationenDSMM XI study: dose definition for intravenous cyclophospham...

DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma

Standard

DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma. / Kropff, Martin; Liebisch, Peter; Knop, Stefan; Weisel, Katja; Wand, Hannes; Gann, Claudia-Nanette; Berdel, Wolfgang E; Einsele, Herrmann; Deutsche Studiengruppe Multiples Myelom, DSMM.

in: ANN HEMATOL, Jahrgang 88, Nr. 11, 11.2009, S. 1125-30.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kropff, M, Liebisch, P, Knop, S, Weisel, K, Wand, H, Gann, C-N, Berdel, WE, Einsele, H & Deutsche Studiengruppe Multiples Myelom, DSMM 2009, 'DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma', ANN HEMATOL, Jg. 88, Nr. 11, S. 1125-30. https://doi.org/10.1007/s00277-009-0726-6

APA

Kropff, M., Liebisch, P., Knop, S., Weisel, K., Wand, H., Gann, C-N., Berdel, W. E., Einsele, H., & Deutsche Studiengruppe Multiples Myelom, DSMM (2009). DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma. ANN HEMATOL, 88(11), 1125-30. https://doi.org/10.1007/s00277-009-0726-6

Vancouver

Kropff M, Liebisch P, Knop S, Weisel K, Wand H, Gann C-N et al. DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma. ANN HEMATOL. 2009 Nov;88(11):1125-30. https://doi.org/10.1007/s00277-009-0726-6

Bibtex

@article{adda803cc42145dfb004db3241af340a,
title = "DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma",
abstract = "A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM). Thirty patients were treated with three 21-day cycles of bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900, 1,200, or 1,500 mg/m(2) on day 1. The maximum tolerated dose of cyclophosphamide was defined as 900 mg/m(2). At this dose level, 92% of patients achieved at least a partial response. The overall response rate [complete response (CR) plus partial response (PR)] across all dose levels was 77%, with a 10% CR rate. No patient experienced progressive disease. The most frequent adverse events were hematological and gastrointestinal toxicities as well as neuropathy. The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.",
keywords = "Adult, Antineoplastic Combined Chemotherapy Protocols, Boronic Acids, Bortezomib, Combined Modality Therapy, Cyclophosphamide, Dexamethasone, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Gastrointestinal Diseases, Hematologic Diseases, Hematopoietic Stem Cell Transplantation, Humans, Infusions, Intravenous, Male, Maximum Tolerated Dose, Middle Aged, Multiple Myeloma, Nervous System Diseases, Prospective Studies, Protease Inhibitors, Pyrazines, Remission Induction, Clinical Trial, Journal Article, Multicenter Study",
author = "Martin Kropff and Peter Liebisch and Stefan Knop and Katja Weisel and Hannes Wand and Claudia-Nanette Gann and Berdel, {Wolfgang E} and Herrmann Einsele and {Deutsche Studiengruppe Multiples Myelom, DSMM}",
year = "2009",
month = nov,
doi = "10.1007/s00277-009-0726-6",
language = "English",
volume = "88",
pages = "1125--30",
journal = "ANN HEMATOL",
issn = "0939-5555",
publisher = "Springer",
number = "11",

}

RIS

TY - JOUR

T1 - DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma

AU - Kropff, Martin

AU - Liebisch, Peter

AU - Knop, Stefan

AU - Weisel, Katja

AU - Wand, Hannes

AU - Gann, Claudia-Nanette

AU - Berdel, Wolfgang E

AU - Einsele, Herrmann

AU - Deutsche Studiengruppe Multiples Myelom, DSMM

PY - 2009/11

Y1 - 2009/11

N2 - A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM). Thirty patients were treated with three 21-day cycles of bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900, 1,200, or 1,500 mg/m(2) on day 1. The maximum tolerated dose of cyclophosphamide was defined as 900 mg/m(2). At this dose level, 92% of patients achieved at least a partial response. The overall response rate [complete response (CR) plus partial response (PR)] across all dose levels was 77%, with a 10% CR rate. No patient experienced progressive disease. The most frequent adverse events were hematological and gastrointestinal toxicities as well as neuropathy. The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.

AB - A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM). Thirty patients were treated with three 21-day cycles of bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900, 1,200, or 1,500 mg/m(2) on day 1. The maximum tolerated dose of cyclophosphamide was defined as 900 mg/m(2). At this dose level, 92% of patients achieved at least a partial response. The overall response rate [complete response (CR) plus partial response (PR)] across all dose levels was 77%, with a 10% CR rate. No patient experienced progressive disease. The most frequent adverse events were hematological and gastrointestinal toxicities as well as neuropathy. The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.

KW - Adult

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Boronic Acids

KW - Bortezomib

KW - Combined Modality Therapy

KW - Cyclophosphamide

KW - Dexamethasone

KW - Dose-Response Relationship, Drug

KW - Drug Administration Schedule

KW - Female

KW - Gastrointestinal Diseases

KW - Hematologic Diseases

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Infusions, Intravenous

KW - Male

KW - Maximum Tolerated Dose

KW - Middle Aged

KW - Multiple Myeloma

KW - Nervous System Diseases

KW - Prospective Studies

KW - Protease Inhibitors

KW - Pyrazines

KW - Remission Induction

KW - Clinical Trial

KW - Journal Article

KW - Multicenter Study

U2 - 10.1007/s00277-009-0726-6

DO - 10.1007/s00277-009-0726-6

M3 - SCORING: Journal article

C2 - 19274460

VL - 88

SP - 1125

EP - 1130

JO - ANN HEMATOL

JF - ANN HEMATOL

SN - 0939-5555

IS - 11

ER -